Global rare disease policy shifts are reshaping orphan drug development, with major implications for equitable access in the UK, EU and US.
From April 2026, NICE raises its cost-effectiveness threshold to £25k–£35k per QALY. What it means for NHS funding, patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results